Reata Pharmaceuticals (RETA): Reiterating Rating And PT As CATALYST Trial Gets Off The Ground - Piper Jaffray

October 7, 2016 7:13 AM EDT
Get Alerts RETA Hot Sheet
Price: $22.98 +0.26%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 5 | Down: 9 | New: 6
Trade RETA Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Reata Pharmaceuticals (NASDAQ: RETA) after the company announced it dosed the first CTD-PAH patient in its Phase III CATALYST trial of lead candidate bardoxolone.

The analyst is encouraged to see CATALYST get off the ground and his research suggests that there is high investigator/patient interest in the program and that this is a conservatively powered,capital-efficient, trial which should accelerate to deliver pivotal results by early ’18.

Reata also announced expanded results from a larger group of CTD-PAH patients (now n=22, up from single digits) treated in the Phase II LARIAT trial. The analyst views this update as addressing key investor questions on replicability of results with Bard, as well as risk-reducing for CATALYST in terms of having well-informed the powering, dosing and patient selection, for the study.

No change to the price target of $33.

For an analyst ratings summary and ratings history on Reata Pharmaceuticals click here. For more ratings news on Reata Pharmaceuticals click here.

Shares of Reata Pharmaceuticals closed at $28.01 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment